ES2065400T3 - Esteroides aromaticos sustituidos con acidos fosfonicos como inhibidores de esteroide-5-alfa-reductasa. - Google Patents

Esteroides aromaticos sustituidos con acidos fosfonicos como inhibidores de esteroide-5-alfa-reductasa.

Info

Publication number
ES2065400T3
ES2065400T3 ES89313258T ES89313258T ES2065400T3 ES 2065400 T3 ES2065400 T3 ES 2065400T3 ES 89313258 T ES89313258 T ES 89313258T ES 89313258 T ES89313258 T ES 89313258T ES 2065400 T3 ES2065400 T3 ES 2065400T3
Authority
ES
Spain
Prior art keywords
alpha
steroid
phosphonic acids
reductase inhibitors
steroids substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89313258T
Other languages
English (en)
Inventor
Dennis Alan Holt
Mark Alan Levy
Brian Walter Metcalf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2065400T3 publication Critical patent/ES2065400T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPONENTES DE ESTRUCTURA (I) EN LA QUE LAS LINEAS DOTADAS INDICAN LA PRESENCIA OPCIONAL DE UN DOBLE ENLACE, X1, X2 Y X3 SON H, HALOGENO, CF3, ALQUIL C1-6, ALCOXI C1-6, CN, NO2, N(R1)2, CHO O CO2R; R1 ES H O ALQUIL C1-8 Y R ES HIDROGENO, HIDROXI O ACETOXI; PROCESOS PARA SU PREPARACION , COMPOSICIONES QUE LOS CONTIENEN Y SU USO EN MEDICINA COMO INHIBIDORES DE REDUCTASA-A-5.
ES89313258T 1988-12-23 1989-12-19 Esteroides aromaticos sustituidos con acidos fosfonicos como inhibidores de esteroide-5-alfa-reductasa. Expired - Lifetime ES2065400T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/290,056 US4882319A (en) 1988-12-23 1988-12-23 Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase

Publications (1)

Publication Number Publication Date
ES2065400T3 true ES2065400T3 (es) 1995-02-16

Family

ID=23114357

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89313258T Expired - Lifetime ES2065400T3 (es) 1988-12-23 1989-12-19 Esteroides aromaticos sustituidos con acidos fosfonicos como inhibidores de esteroide-5-alfa-reductasa.

Country Status (13)

Country Link
US (1) US4882319A (es)
EP (1) EP0375345B1 (es)
JP (1) JPH02212499A (es)
AT (1) ATE114666T1 (es)
AU (1) AU631587B2 (es)
CA (1) CA2004946A1 (es)
DE (1) DE68919660T2 (es)
DK (1) DK654689A (es)
ES (1) ES2065400T3 (es)
GR (1) GR3015039T3 (es)
IE (1) IE69337B1 (es)
PT (1) PT92720A (es)
ZA (1) ZA899672B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US5026882A (en) * 1988-12-23 1991-06-25 Smithkline Beecham Corporation Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5075450A (en) * 1990-06-28 1991-12-24 Merck & Co., Inc. Intermediates in the synthesis of 17β-acyl-3-carboxy-androsta-3,5-dienes
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
EP0641356B1 (en) * 1991-12-20 1998-04-22 Glaxo Wellcome Inc. Inhibitors of 5-alpha-testosterone reductase
EP0641204B1 (en) * 1992-05-20 2000-08-16 Merck & Co. Inc. 17-ethers and thioethers of 4-aza-steroids
WO1993023039A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. Substituted 4-aza-5a-androstan-ones as 5a-reductase inhibitors
JPH07508033A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド ５α−レダクターゼ阻害剤としての３−オキソ−４−アザステロイドの新規１７−エステル，アミド及びケトン誘導体
WO1993023419A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-ONES AS 5α-REDUCTASE INHIBITORS
CA2135056A1 (en) * 1992-05-20 1993-11-25 Donald W. Graham New delta-17 and delta-20 olefinic and saturated 17b-substituted-4-aza-5a-andros-tan-3-ones as 5a-reductase inhibitors
CA2135057A1 (en) * 1992-05-20 1993-11-25 Bruce E. Witzel 17-amino substituted 4-azasteroid 5a-reductase inhibitors
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
WO1993023048A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 4-azasteroid 5-alpha-reductase inhibitors
EP0649306B1 (en) * 1992-05-20 2001-01-10 Merck & Co. Inc. Ester derivatives of 4-aza-steroids
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9213901D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Compounds
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
US5302589A (en) * 1992-08-07 1994-04-12 Glaxo, Inc. Heterocyclic inhibitors of 5-α-testosterone reductase
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
WO1994021614A1 (en) * 1993-03-24 1994-09-29 Merck & Co., Inc. SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5α-REDUCTASE INHIBITORS
ATE158301T1 (de) * 1993-06-28 1997-10-15 Merck & Co Inc 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5430157A (en) * 1993-12-13 1995-07-04 Eli Lilly And Company Reduced phenanthrenes
US5637310A (en) * 1993-12-20 1997-06-10 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5525608A (en) * 1994-04-20 1996-06-11 Merck & Co., Inc. 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
JP3816550B2 (ja) * 1994-11-07 2006-08-30 キヤノンファインテック株式会社 プリント媒体搬送装置およびラベルプリンタ
US6054446A (en) * 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6548491B2 (en) * 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
WO1999061055A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
CN101287411B (zh) 2005-04-28 2013-03-06 普罗秋斯生物医学公司 药物信息系统及其用途
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
NZ594310A (en) 2009-02-20 2014-02-28 To Bbb Holding B V Glutathione-based drug delivery system
MX2011011833A (es) 2009-05-06 2012-01-27 Lab Skin Care Inc Composiciones de administración dérmica que comprenden complejos de partículas de fosfato de calcio-agente activo y métodos para utilizar las mismas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049498A (en) * 1973-11-29 1979-02-27 Gunther Kruger Steroid compounds and processes therefor
AU534679B2 (en) * 1979-03-15 1984-02-09 Commonwealth Scientific And Industrial Research Organisation Steroid immunogens
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US5026882A (en) * 1988-12-23 1991-06-25 Smithkline Beecham Corporation Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase

Also Published As

Publication number Publication date
EP0375345B1 (en) 1994-11-30
EP0375345A1 (en) 1990-06-27
IE69337B1 (en) 1996-09-04
CA2004946A1 (en) 1990-06-23
ATE114666T1 (de) 1994-12-15
US4882319A (en) 1989-11-21
DK654689D0 (da) 1989-12-21
AU631587B2 (en) 1992-12-03
DK654689A (da) 1990-06-24
IE894107L (en) 1990-06-23
DE68919660T2 (de) 1995-05-24
PT92720A (pt) 1990-06-29
DE68919660D1 (de) 1995-01-12
AU4699589A (en) 1990-06-28
GR3015039T3 (en) 1995-05-31
JPH02212499A (ja) 1990-08-23
ZA899672B (en) 1990-11-28

Similar Documents

Publication Publication Date Title
ES2065400T3 (es) Esteroides aromaticos sustituidos con acidos fosfonicos como inhibidores de esteroide-5-alfa-reductasa.
ES2067557T3 (es) Esteroides aromaticos sustituidos con acido fosfinico como inhibidores de la esteroide 5-d-reductasa.
ZA899669B (en) Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-alpha-reductase
HUT55795A (en) Process for producing aromatic steroide 5-alpha-reductase inhibitors and pharmaceutical compositions containing them
IT8667371A1 (it) Composizioni topiche per il trattamento della pelle a base di derivati dell'acido salicilico.
DK196691A (da) Steroid-5-alfa-reduktaseinhibitorer
NO174964C (no) Analogifremgangsmåte for fremstilling av aromatiske inhibitorer for steroid 5-
ATE110736T1 (de) Phosphonsäure-derivate von steroiden als hemmstoffe der 5-alpha-reduktase.
ATE91625T1 (de) Verwendung von porphyrinderivaten bei der entdeckung und behandlung von tumoren.
PT89788A (pt) Processo de preparacao de derivados da quinolina substituidas e de composicoes farmaceuticas que os contem
IL90056A (en) Topical pharmaceutical compositions containing 4-quinoline carboxylic acid derivatives
DE3766334D1 (de) Lysinsalz der 4-biphenylessigsaeure und es enthaltende augenheilmittel.
ES2095542T3 (es) Nuevos ciclopentanperhidrofenantren-17beta-(hidroxi o alcoxi)-17alfa-(aril o heterociclil)-3beta-derivados activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos.
FI88359C (fi) Foerfarande foer framstaellning av en kardiovaskulaer komposition att anvaendas lokalt
ATE32883T1 (de) Derivate von biphenylylalkansaeuren, verfahren zur herstellung und pharmazeutische zusammensetzungen daraus.
IT8520908A0 (it) Sali doppi di derivati dell'acido desossicolico, loro impiego eprocedimento per la loro preparazione.
IT1173763B (it) Derivati dell'acido 3-mercapto-2-oxo-1-pirrolidinacetico,procedimento di preparazione e composizioni farmaceutiche che li contengono

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 375345

Country of ref document: ES